The Centers for Medicare and Medicaid Services should reduce its planned 14.5% Medicare Part B monthly premium increase for 2022 until it has a better idea of how much it will actually spend on Biogen, Inc./Eisai Co., Ltd.’s Aduhelm and similar Alzheimer’s drugs, according to Senate Finance Committee chairman Ron Wyden, D-Ore.
CMS announced the unprecedented increase in November, explaining that about half of the premium hike will go toward setting up...